European CHMP recommends approval of MenQuadfi (meningococcal vaccine) for prophylaxis against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y

MenQuadfi is intended for use for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. Final approval is awaited.

Source:

European Medicines Agency